GlassScriptPhysician profile
Rocco F Loccisano
NPI 1316963119
$5,415.96
in general payments reported to CMS, 2019-2025
23 companies · $1,567 in 2025
The $1,567 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $242 · 2021: $438 · 2022: $294 · 2023: $905 · 2024: $1,222 · 2025: $1,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,674 · Consulting Fee: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,674.02 |
| Consulting Fee | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,358.21 | 2022-2025 | Miebo, Xiidra, Infuse |
| Astellas Pharma US INC | $607.67 | 2023-2025 | Izervay |
| Alcon Vision LLC | $545.61 | 2023-2025 | Tryptyr, Total30, Eysuvis |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $448.84 | 2019-2021 | |
| Allergan, INC. | $384.52 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $333.90 | 2024-2025 | Xdemvy |
| Coopervision INC. | $267.40 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Abbvie INC. | $211.59 | 2023-2024 | |
| Glaukos Corporation | $198.94 | 2021-2025 | Photrexa Viscous and Photrexa |
| Novartis Pharmaceuticals Corporation | $142.24 | 2020-2023 | |
| Johnson & Johnson Vision Care, INC. | $133.54 | 2021-2024 | Acuvue |
| Sight Sciences, INC. | $126.18 | 2023 | Omni Surgical System |
| Amgen INC. | $121.84 | 2024 | Tepezza |
| Aerie Pharmaceuticals, INC. | $94.03 | 2019 | |
| Spark Therapeutics, INC. | $91.82 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $67.95 | 2019 | |
| Lkc Technologies, INC. | $66.77 | 2022 | |
| Carl Zeiss Meditec Ag | $58.20 | 2020 | |
| Optos, INC. | $47.45 | 2019 | |
| Biotissue Holdings INC. | $39.64 | 2022-2025 | |
| Oyster Point Pharma, INC. | $32.48 | 2022-2024 | Ryzumvi |
| Sun Pharmaceutical Industries INC. | $25.97 | 2025 | |
| Kala Pharmaceuticals, INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rocco Loccisano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.